02:17 , Feb 24, 2017 |  BC Week In Review  |  Company News

J&J, Akebia deal

Johnson & Johnson’s Janssen Pharmaceutica N.V. company granted Akebia exclusive, worldwide rights to develop and commercialize a portfolio of preclinical inflammatory bowel disease small molecules that target hypoxia-inducible factor (HIF), including AKB-5169 (formerly JNJ5169). The...